4D Molecular Therapeutics... (FDMT)
4.98
0.10 (2.05%)
At close: Jan 15, 2025, 12:42 PM
Ratios (Annual)
Discover comprehensive ratio statement breakdowns that reveal insights into revenue, expenses, and beyond.
| Year | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 |
| PE Ratio | -7.86 | -7.11 | -8.91 | -19.56 | -20.27 | -53.08 | -53.54 |
| PS Ratio | 38.26 | 229.63 | 33.73 | 81.25 | 153.59 | 35.88 | 103.77 |
| PB Ratio | 2.58 | -2.28 | -2.94 | 4.31 | -14.7 | -18.38 | -30.67 |
| P/FCF Ratio | -10.09 | -7.32 | -7.78 | -21.31 | -26.88 | -30.42 | 78.40 |
| P/OCF Ratio | -10.46 | -8.29 | -8.8 | -21.72 | -29.23 | -31.2 | 72.94 |
| OCF/S Ratio | -3.66 | -27.7 | -3.83 | -3.74 | -5.25 | -1.15 | 1.42 |
| Debt / Equity Ratio | 0.05 | -0.05 | -0.08 | n/a | n/a | n/a | n/a |
| Quick Ratio | 15.65 | 14.39 | 19.83 | 16.88 | 4.05 | 11.68 | 4.15 |
| Current Ratio | 15.65 | 14.02 | 19.31 | 16.88 | 4.05 | 11.68 | 4.15 |
| Asset Turnover | 0.06 | 0.01 | 0.05 | 0.05 | 0.12 | 0.15 | 0.21 |
| Interest Coverage | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Return on Equity (ROE) | -0.33 | 0.32 | 0.33 | -0.22 | 0.73 | 0.35 | 0.57 |
| Return on Assets (ROA) | -0.3 | -0.39 | -0.19 | -0.2 | -0.91 | -0.1 | -0.41 |
| Return on Capital (ROIC) | -0.35 | -0.45 | -0.21 | -0.21 | -1.12 | -0.12 | -0.53 |
| Dividend Yield | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Payout Ratio | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Gross Profit Margin | -368.54% | -24% | 83.26% | -289.64% | -454.22% | -29.95% | -134.42% |
| Net Profit Margin | -486.59% | -3.23K% | -378.63% | -415.38% | -757.79% | -67.59% | -193.83% |
| Pretax Profit Margin | -486.59% | -3.44K% | -395.37% | -416.49% | -705.78% | -67.59% | -193.83% |
| Operating Profit Margin | -544.65% | -3.52K% | -395.46% | -416.28% | -726.65% | -73.6% | -194.68% |
| FCF Margin | -379.11% | -3.14K% | -433.77% | -381.35% | -571.34% | -117.95% | 132.37% |
| EBITDA Margin | -516.9% | -3.39K% | -378.72% | -405.68% | -638.75% | -68.66% | -183.87% |